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Anaplastic thyroid carcinoma (ATC) is a very aggressive humanmalignancy, having amarked degree of invasiveness and no features
of thyroid differentiation. It is known that eitherHDAC inhibitors or PARP inhibitors have antiproliferative effects on thyroid cancer
cells. Therefore, in this study the possible synergy between the two types of compounds has been investigated. The ATC-derived
cell line SW1736 has been treated with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and the PARP inhibitor PJ34,
alone or in combination. In terms of cell viability, the combination index value was always lower than 1 at various tested dosages,
indicating, therefore, synergy in a wide range of doses for both compounds. Synergy was also observed in induction of apoptosis.
In terms of thyroid-specific gene expression, synergy was observed for TSHRmRNA levels but not for NIS, TTF1, TTF2, and PAX8
mRNA levels. Altogether, these data suggest that the combined use of HDAC and PARP inhibitors may be a useful strategy for
treatment of ATC.
1. Introduction
Thyroid cancer is the most common endocrine malignancy,
and its incidence has continuously increased in the last three
decades all over the world [1]. Thyroid cancers are typically
classified as papillary (PTC), follicular (FTC), medullary
(MTC), or anaplastic (ATC) carcinomas.
ATC is one of the most aggressive human malignancies.
These tumors have a marked degree of invasiveness and
extensive necrosis and there are no features of thyroid differ-
entiation [2]. The mechanisms underlying the development
of ATCs are incompletely understood. Currently, available
therapy for ATCs includes chemotherapy, radiotherapy, and
surgery [3]. Nonetheless, patients with ATC still have a
median survival of 5 months and less than 20% survive 1 year.
Furthermore early tumor dissemination results in 20–50%
percent of patients having distant metastases and 90% having
adjacent tissue invasion on presentation [2].
HDAC inhibitors (HDACIs) are a group of small mole-
cules that promote gene transcription by chromatin remod-
eling and have been extensively studied as potential drugs
for treating cancer. Luong et al. have established that the
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA),
already FDA-approved for the treatment of several neoplastic
diseases [4, 5], has antitumor activities against thyroid cancer
[6].
Inhibitors of the poly(ADP-ribose) polymerases (PARPs)
family are currently being evaluated as potential anticancer
drugs. PARPs have a key role in a large number of cell viability
processes as DNA repair, genome integrity, regulation of
transcription, proliferation, and apoptosis [7].
Different independent studies have demonstrated that the
combination of both HDAC inhibitors and PARP inhibitors
with other drugs could result in synergistic effects on their
antitumor activities if compared to those observed using
single agents [8, 9].
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Current cancer therapy should satisfy requirements for
targeted elimination of cancer cells simultaneously with life-
compatible adverse effects [10]. One of the main tenets
of cancer therapeutics is that combinations of anticancer
agents with different targets or different mechanisms of
action and varied normal tissue toxicities will produce better
therapeutic outcomes [11] by decreasing single drugs doses
and minimizing or slowing drug resistance development. In
this study, we investigated the possible use of SAHA, an
HDAC inhibitor, and PJ34, a PARP inhibitor, in combination,
in a cellular model of anaplastic thyroid cancer.
2. Material and Methods
2.1. Cell Line and Treatments. SW1736, human cell line
derived from anaplastic thyroid cancer, was grown in
RPMI 1640 medium (EuroClone, Milan, Italy) supple-
mented with 10% fetal bovine serum (Gibco Invitrogen,
Milan, Italy) and 50mg/mL gentamicin (Gibco Invitro-
gen, Milan, Italy) in a humidified incubator (5% CO
2
in
air at 37∘C). The identity of SW1736 cells was demon-
strated by evaluating the following STRs: D16S539, THO1,
vWA, D3S1358, D21S11, and D18S51; the obtained genotype
was identical to those reported by the CLS Cell Lines
Service GmbH (http://www.cell-lines-service.de/). Cultured
cells were treated with the following agents, either alone or
in combination, as described in the text: SAHA (1–4𝜇M in
DMSO) (Cayman Chemical, Michigan, USA) and PJ34 (5–
30 𝜇M in nuclease-free water) (Merck Chemicals Ltd). These
concentrations are consistent with those utilized for in vivo
studies [12, 13]. All treatments were done for 72 hours.
2.2. Cell Viability. To test cell viability, CellTiter-Blue Cell
Viability assay (Promega, Milano, Italy) was used according
to the manufacturer’s instructions. Cells were seeded onto
96-well plates in 200𝜇L medium. The next day, the growth
medium was replaced with fresh medium containing DMSO
as vehicle (untreated cultures) or SAHA and PJ34 alone or
in combination. For each treatment quadruplicate wells were
used.
2.3. Combination Index (CI Value). Effects of drugs combina-
tion used in this study were evaluated using the combination
index equation based on the multiple drug-effect equation of
Chou-Talalay [14, 15]. In all cases where CI value could be
determined the following diagnostic rule was applied: CI <
1 indicates synergism, CI = 1 indicates additive effect, and
CI > 1 indicates antagonism. The analysis was obtained on
CompuSyn software (ComboSyn Inc., Paramus, USA).
2.4. Annexin V Staining. Cells were treated with appropriate
drugs as described and then they were washed with cold
PBS, transferred to a polystyrene round-bottomed flow tube
(Falcon, Becton Dickinson, Franklin Lakes, NY, USA), and
resuspended in 195 𝜇L of 1× binding buffer (BB-10mM
Hepes/NaOH, pH 7.4, 140mM NaCl, and 2.5mM CaCl
2
).
To the suspension, 5 𝜇L of fluorescein-conjugated Annexin
V (Annexin V-FITC; Bender Med Systems, Wien, Austria)
was added and samples were incubated for 10min at room
temperature. After washing, cells were resuspended in 190𝜇L
of BB inwhich 10 𝜇L of propidium iodide stock solution (final
concentration 1𝜇g/mL) was added. Flow cytometry analysis
was done on CyAN, Dako Cytomation using the Summit
software.
2.5. Quantitative RT-PCR. Total RNA from cell line, treated
for 72 h with SAHA 1 𝜇M and PJ34 15 𝜇M alone or in com-
bination, was extracted with RNeasy mini kit according to
manufacturer’s instructions (Qiagen, Hilden, Germany).
500 ng of total RNA was reversely transcripted to cDNA
using random exaprimers and MMLV reverse transcriptase
(Invitrogen). Real-time PCRs were performed using TaqMan
Universal PCR Master Mix (Applied Biosystems) with the
ABI Prism 7300 Sequence Detection Systems (Applied Biosy-
stems, Foster City, CA, USA). The ΔΔCT method, by means
of the SDS software (Applied Biosystems), was used to calc
ulate the mRNA levels. Oligonucleotide primers were purch
ased from Life Technologies and were as follows: 𝛽-actin
5󸀠 primer CGAGCGCGGCTACAGCTT, 𝛽-actin probe
ACCACCACGGCCGAGCGG, and 𝛽-actin 3󸀠 primer TCC-
TTAATGTCACGCACGATTT; PAX8 5󸀠 primer CAACAG-
CACCCTGGACGAC, PAX8 3󸀠 primer AGGGTGAGTGAG-
GATCTGCC, and PAX8 probe CTGACCCCTTCCAAC-
ACGCCACTG; NIS Hs00166567 m1; TTF1 Hs00968940 m1;
TTF2 Hs00916085 s1; and TSHR Hs01053846 m1.
2.6. Statistical Analysis. Cell viability, apoptosis, and mRNA
levels were expressed as means ± SD, and significances were
analyzed with the t test performed with GraphPAD Software
for Science (San Diego, CA, USA).
3. Results
In a first set of experiments, single effects of the HDAC
inhibitor SAHA and the PARP inhibitor PJ34 on cell viability
of the human anaplastic thyroid cancer-derived cell line
SW1736 were investigated. Cell viability was assessed after
treatment with different doses of SAHA and PJ34 for 72
hours (Figure 1). Both SAHA and PJ34 alone inhibited cell
proliferation in a dose-dependent manner; however, at the
utilized doses, SAHA seemed to have a greater effect, causing
a more significant decrease in cell viability compared to cells
treated by PJ34. Thus, both compounds alone were able to
inhibit proliferation of SW1736 cells. We then tested synergy
of the two compounds by measuring CI values of different
drug combinations according to the Chou-Talalay equation
[14, 15]. As indicated in Table 1, all combinations used showed
a very high decrease in cell growth compared to untreated
cells (always the CI values were lower than 1). Our results
indicated that SAHA and PJ34 have a synergic effect in
decreasing cell proliferation in a quite high range of utilized
doses.
We focused on the SAHA 1 𝜇M and PJ34 15 𝜇M combi-
nation which generated the lowest CI value. As represented
in Figure 2, the treatment with SAHA 1 𝜇M had only a light
effect on SW1736 viability, while PJ34 15𝜇Mreduced cell pro-
liferation more effectively. Using these doses in combination
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Figure 1: Effects of HDAC and PARP inhibitors on SW1736 cell
viability. Cells were treated for 72 h with SAHA (1𝜇M–4𝜇M) or
PJ34 (5𝜇M–30 𝜇M), and CellTiter-Blue Cell Viability assay was
performed as described in Section 2. Bars indicate the percentage
of viable cells versus controls (untreated cells) and represent means
± SD of three experiments. ∗ indicates values significantly different
compared to control.
Table 1: Combination index data for SAHA and PJ34 combination.
Dose SAHA
(𝜇M)
Dose PJ34
(𝜇M)
Combination effect
(% cell viability)∗ CI value
1.0 5.0 26 0.26979
1.0 10.0 37 0.60235
1.0 15.0 12 0.13878
1.0 30.0 13 0.18473
2.0 5.0 18 0.33123
2.0 10.0 17 0.33414
2.0 15.0 19 0.40111
2.0 30.0 11 0.25341
3.0 5.0 13 0.36504
3.0 10.0 26 0.75320
3.0 15.0 16 0.47175
3.0 30.0 14 0.45413
4.0 5.0 17 0.60763
4.0 10.0 17 0.62785
4.0 15.0 10 0.40318
4.0 30.0 13 0.53865
∗Mean value of four replicates. In each condition standard deviation is less
than 10%.
we obtained a strong lowering of cell viability, almost 90%
compared to untreated cells.
Subsequently, we evaluated apoptosis of SW1736 by mea-
surement of Annexin V by fluorescence-activated cell sorting
after treatments with SAHA 1 𝜇M and PJ34 15 𝜇M, alone or
in combination (Figure 3(a)). The percentage of apoptotic
cells (AnnexinV-positive/PI-negative) was 1.98%with SAHA
1 𝜇M and 1.99% with PJ34 15 𝜇Mwhile after the combination
treatment, it reached 8.16% (Figure 3(b)).
We next tested if synergy between the two compounds
was present on expression of several thyroid-specific genes.
Effects on mRNA levels were evaluated by real-time PCR.
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Figure 2: Effect of HDAC and PARP inhibitors combination
on SW1736 cell viability. Cells were treated for 72 h with SAHA
1 𝜇M and PJ34 15 𝜇M, alone or in combination. CellTiter-Blue
Cell Viability assay was performed as described in Section 2. Bars
indicate the percentage of viable cells versus controls (untreated
cells) and represent means ± SD of four experiments. ∗ indicates
values significantly different compared to all other conditions.
Among all genes analyzed synergy between the two com-
pounds was detectable only for TSHR gene (Figure 4). The
72-hour treatment with SAHA 1 𝜇M induced a marked effect
on TSHR mRNA expression, while PJ34 15 𝜇M did not have
any remarkable effect compared to the control cells. However,
by using the two drugs in combination we obtained a strong
effect on TSHR mRNA levels, significantly higher than all
other conditions, with an increment of 36-fold of induction
compared to the control.
4. Discussion
Developing a pharmacological treatment against cancer, the
central issue consists in increasing therapeutic index and,
at the same time, limiting development of resistance. One
solution is to combine multiple drugs that act synergistically,
and, in fact, a large number of ongoing clinical trials are
investigating the effects of combined therapy against differ-
ent types of cancer [16, 17]. In developing new strategies
for treatment of anaplastic thyroid cancer, combinations of
HDAC inhibitors and other drugs have been attempted [18–
24]. However, neither in preclinical nor in clinical settings of
thyroid cancer treatment, the combination between HDAC
and PARP inhibitors has been investigated. It is increasingly
clear that cancer is not only caused by genetic factors but can
also be considered a epigenetics disease [25] and epigenetic
enzymes can, therefore, be considered as novel therapeutic
targets. Accordingly, both HDAC and PARP inhibitors can
be considered as epigenetic drugs. Combinations of HDAC
and PARP inhibitors have been tested in different kinds
of neoplastic diseases. By using hepatocellular carcinoma
cell lines, a synergistic inhibition of cell growth by SAHA
and the PARP inhibitor olaparib has been demonstrated
[26]. Inhibition of cell proliferation was associated with
increase of apoptosis levels, accumulation of DNA damage,
and modification of the cAMP signaling pathway. Combined
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Figure 3: Combination of SAHA and PJ34 induces apoptosis in SW1736 cell line. In (a) Annexin V (FITC) and propidium iodide (PI)
staining of anaplastic thyroid cancer cell line after 72 h treatment with SAHA 1𝜇M, PJ34 15 𝜇Malone or in combination. In (b) representation
of Annexin V-positive/PI-negative cells.
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Figure 4: Expression levels of PAX8, NIS, TTF1, TTF2, and TSHR genes in SW1736 cell line. RNA extraction and real-time PCR are described
in Section 2. For each gene the results were normalized against 𝛽-actin and expressed in arbitrary unit (2−ΔCt). Each bar represents the mean
value of three different determinations. For each bar standard deviation is not above 10%of each value.∗ indicates values significantly different
compared to all other conditions.
effects of SAHA and PJ34 on leukemia cell lines have been
investigated [27]. Also in that study, synergistic effects on
proliferation inhibition and apoptosis increase have been
observed. Recently, synergy between SAHA and olaparib has
been observed even in ovarian cancer cell lines [28]. We have
recently obtained similar effects on breast cancer cell lines
(unpublished data).
Effects of HDAC and PARP inhibitors alone have been
previously investigated by our group. We have shown that
HDAC inhibitors affect cell proliferation and expression of
various genes in several thyroid cancer cell lines [29, 30].
Moreover Lavarone et al. have recently shown that PJ34
inhibits cell growth and increases NIS expression in various
thyroid cancer cell lines [31]. In this research we demonstrate
that HDAC and PARP inhibitors have a synergistic effect
on proliferation of a human anaplastic thyroid-derived cell
line. Thus, synergy between these two classes of compounds
appears to be a common phenomenon in cancer cell lines
of various origins, underlying the potential role of these
combinations as an interesting strategy for cancer therapy.
Our obtained CI values indicate that synergy between SAHA
and PJ34 occurs in a wide range of doses, suggesting that the
combined effect could probably be observed also in vivo.
In addition to the impact on cell proliferation, we
have investigated effects of the SAHA-PJ34 combination on
thyroid-specific genes expression. Regarding thyroid-specific
transcription factors, the SAHA-PJ34 combination induces a
TTF1 slight decrease, a TTF2 slight increase, and no change
in PAX8. Such behavior indicates that the control of these
genes expression occurs through distinct mechanisms. This
6 International Journal of Endocrinology
view agrees with previous studies in which control of thyroid-
specific transcription factors expression has been investigated
[32].
Synergy between SAHA and PJ34 in increasing mRNA
levels of TSHR was observed. The TSHR is localized in the
plasmamembrane, and, thus, it has been proposed as a target
to direct therapeutic compounds into thyroid cancer cells
[33–36]. Our data would suggest that the combined use of
HDAC and PARP inhibitors may facilitate such approach.
Differently from TSHR, NIS gene expression is reduced
by SAHA alone and in combination with PJ34. Such a
different effect between these genes expression is not unex-
pected. TSHR and NIS have a different regulation in terms
of gene expression. It is well known, for example, that during
tumorigenesis NIS is one of the earliest downregulated genes,
while TSHR is among the latest ones [37, 38].
In conclusion, considering our data on cell proliferation
and gene expression altogether, the combined use of HDAC
and PARP inhibitors can be a useful strategy for ATC
treatment. Preclinical in vivo studies are required to validate
such a possibility.
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